Charles River Laboratories International, Inc. (CRL) Stock

Charles River Laboratories International, Inc. is a leading contract research organization specializing in non-clinical services for drug discovery, development, and safety testing across global markets including the United States, Europe, Canada, the Asia Pacific, and beyond. Operating through three core segments, the company offers comprehensive solutions tailored to pharmaceutical, biotechnology, and medical device industries.

The Research Models and Services (RMS) segment plays a pivotal role in producing and distributing rodent research models, genetically engineered models, and purpose-bred rats and mice. These models are crucial for researchers conducting preclinical studies and drug screening processes. Additionally, RMS provides ancillary services such as insourcing solutions and diagnostic services to support research animal health.

The Discovery and Safety Assessment (DSA) segment specializes in early-stage discovery services aimed at identifying and validating novel drug targets and therapeutic candidates. It also offers extensive safety assessment services encompassing toxicology, pathology, safety pharmacology, bioanalysis, and pharmacokinetics. These services are pivotal in ensuring the safety and efficacy of pharmaceutical and biotechnological products before clinical trials and market launch.

Charles River Laboratories' Manufacturing Solutions segment delivers advanced in vitro testing methods for pharmaceuticals and consumer products, including rapid quality control tests for both sterile and non-sterile products. Moreover, it provides specialized testing services for biologics outsourced by pharmaceutical firms and offers avian vaccine solutions, supplying specific-pathogen-free (SPF) fertile chicken eggs and diagnostic products essential for vaccine production. The company also manages contract vivarium operations tailored to biopharmaceutical clients, enhancing operational efficiencies in research and development processes.